First Major Advance in Treatment of Lung Cancer in Years

Publication
Article
OncologyONCOLOGY Vol 13 No 3
Volume 13
Issue 3

A cooperative national clinical trial has produced the first major treatment advance in years for small-cell lung cancer. The study, which was published in the February 1999 issue of the New England Journal of Medicine, used two treatments of radiation daily, combined with chemotherapy, compared to the usual practice of delivering one radiation dose per day. Specifically, the protocol covered small-cell lung cancer limited to one-half of the chest area.

A cooperative national clinical trial has produced the first major treatment advance in years for small-cell lung cancer. The study, which was published in the February 1999 issue of the New England Journal of Medicine, used two treatments of radiation daily, combined with chemotherapy, compared to the usual practice of delivering one radiation dose per day. Specifically, the protocol covered small-cell lung cancer limited to one-half of the chest area.

Cooperating in the trial were the Radiation Therapy Oncology Group (RTOG), the Eastern Cooperative Oncology Group (ECOG), and the Southwest Oncology Group (SWOG).

“Radiation to the chest confined to one lung and adjacent lymphatics improves survival,” according to lead author Andrew T. Turrisi, III, md. “But there has been lack of agreement on the best ways to integrate thoracic radiotherapy and chemotherapy for this form of lung cancer.” Dr. Turrisi is professor and chairman of the Department of Radiation Oncology, Medical University of South Carolina, Charleston.

Improved Survival

He explained that the cooperative trial involved 417 patients with limited, small-cell lung cancer. All received chemotherapy with cisplatin (Platinol) plus etoposide, but some received radiation once a day, while others received it twice a day. The radiation dose was identical.

The patients who received two radiation treatments daily plus chemotherapy had overall survival rates of 47% at 2 years and 26% at 5 years. Those receiving one radiotherapy treatment daily had rates of 41% and 16% for the comparable time periods.

The overall survival rates for the two groups of patients were 44% at 2 years and 23% at 5 years, he added. “This represents a considerable improvement in survival rates over previous results in patients with limited, small-cell lung cancer.”

For further information about RTOG clinical trials, call Nancy Smith at 215-574-3205.

Articles in this issue

WHO Declares Lymphatic Mapping to Be the Standard of Care for Melanoma
Rituximab: Phase II Retreatment Study in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma
Response Criteria for NHL: Importance of “Normal” Lymph Node Size and Correlations With Response
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
A Randomized Trial of Fludarabine, Mitoxantrone (FM) Versus Doxorubicin, Cyclophosphamide, Vindesine, Prednisone (CHEP) as First Line Treatment in Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma: A Multicenter Study by GOELAMS Group
Navelbine Increased Elderly Lung Cancer Patients’ Survival
Fludarabine Versus Conventional CVP Chemotherapy in Newly C Diagnosed Patients With Stages III and IV Low-Grade Malignant Non-Hodgkin’s Lymphoma: Preliminary Results From a Prospective, Randomized Phase III Clinical Trial in 381 Patients
Multicenter, Phase III Study of Iodine-131 Tositumomab (Anti-B1 Antibody) for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma
T-Cell–Depleted Allogeneic Bone Marrow Transplant From HLA-Matched Sibling Donors for Non-Hodgkin’s Lymphoma
Consensus Statement on Prevention and Early Diagnosis of Lung Cancer
In Vivo Purging and Adjuvant Immunotherapy With Rituximab During PBSC Transplant For NHL
Fludarabine and Cyclophosphamide: A Highly Active and Well-Tolerated Regimen for Patients With Previously Untreated Indolent Lymphomas
Campath-1H Monoclonal Antibody in Therapy for Advanced Low-Grade Non-Hodgkin’s Lymphomas: A Phase II Study
AIDS Drugs Effective Against Most Common HIV Strain
Rituximab Therapy in Previously Treated Waldenström’s Macroglobulinemia: Preliminary Evidence of Activity
Recent Videos
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Video 3 - "NGS Testing Challenges and Considerations in NSCLC"
Related Content